Schizophrenia Treatment Adherence Investigation (STAI)

Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01001481

Enrollment

550

Registered

2009-10-26

Start date

2007-07-31

Completion date

2009-09-30

Last updated

2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizoaffective Disorder, Schizophrenia

Keywords

Treatment review, Schizophrenia, Observational, Prospective studies, Australia

Brief summary

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.

Detailed description

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered

Interventions

OTHERRisk status for medication adherence

Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV * Currently treated in an outpatient clinic * Able to provide informed consent * Concurrent enrolment in clinical trials is acceptable * Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame
Primary outcome measure is the Clinical Assessment of Adherence as rated by the Investigators	6 months, 12 months

Secondary

Measure	Time frame
Clinical exacerbations (worsening of symptoms)	6 mths, 12 mths
Medication changes	6 mths, 12 mths

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026